Rational Design of Conjugated Photosensitizers with Controllable Photoconversion for Dually Cooperative Phototherapy
Rational Design of Conjugated Photosensitizers with Controllable Photoconversion for Dually Cooperative Phototherapy
复制标题
合理设计用于双重协同光疗的可控光转换共轭光敏剂
DOI：
10.1002/adma.201801216
复制
发表时间：
2018
影响因子：
29.4
通讯作者：
Chen Huabing
中科院分区：
文献类型：
--
作者：
Ye Shuyue;Rao Jiaming;Qiu Shihong;Zhao Jinglong;He Hui;Yan Ziling;Yang Tao;Deng Yibin;Ke Hengte;Yang Hong;Zhao Yuliang;Guo Zhengqing;Chen Huabing
在精确的癌症治疗领域中，高度需要高性能光敏剂来实现选择性肿瘤光消融。然而，由于存在在光疗中存活的残留肿瘤细胞，光敏剂经常遭受有限的肿瘤抑制或不可避免的肿瘤再生长。一个主要的挑战仍然是探索一种有效的方法，以促进显着的光敏剂的光转化，以最大限度地提高抗癌效率。在这里，证明了基于硼二吡咯亚甲基（BDP）的共轭光敏剂（CP）的合理设计，其可以在光暴露时诱导双重协同光疗。BDP单体与二聚体BDP（di-BDP）或三聚体BDP（tri-BDP）的共轭偶联诱导从荧光到单线态到三线态或非辐射跃迁的光转化，以及明显红移到近红外区域的吸收。特别是，纳米颗粒内的tri-BDP在近红外光暴露时显示出更好的转化为主要热效应和次要单线态氧，通过其主导的晚期凋亡和中度早期凋亡引起的协同抗癌效率，显著实现肿瘤光消融而没有任何再生长。这种CP的合理设计可以作为精准医学中合作癌症光疗的有价值的范例。
High‐performance photosensitizers are highly desired for achieving selective tumor photoablation in the field of precise cancer therapy. However, photosensitizers frequently suffer from limited tumor suppression or unavoidable tumor regrowth due to the presence of residual tumor cells surviving in phototherapy. A major challenge still remains in exploring an efficient approach to promote dramatic photoconversions of photosensitizers for maximizing the anticancer efficiency. Here, a rational design of boron dipyrromethene (BDP)‐based conjugated photosensitizers (CPs) that can induce dually cooperative phototherapy upon light exposure is demonstrated. The conjugated coupling of BDP monomers into dimeric BDP (di‐BDP) or trimeric BDP (tri‐BDP) induces photoconversions from fluorescence to singlet‐to‐triplet or nonradiative transitions, together with distinctly redshifted absorption into the near‐infrared region. In particular,tri‐BDP within nanoparticles shows preferable conversions into both primary thermal effect and minor singlet oxygen upon near‐infrared light exposure, dramatically achieving tumor photoablation without any regrowth through their cooperative anticancer efficiency caused by their dominant late apoptosis and moderate early apoptosis. This rational design of CPs can serve as a valuable paradigm for cooperative cancer phototherapy in precision medicine.